Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02535325. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT02535325
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 17 participants
Conditions and interventions
Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- Stage III Lung Adenocarcinoma AJCC v7
- Stage III Lung Large Cell Carcinoma AJCC v7
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Adenocarcinoma AJCC v7
- Stage IIIA Lung Large Cell Carcinoma AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Adenocarcinoma AJCC v7
- Stage IIIB Lung Large Cell Carcinoma AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Lung Adenocarcinoma AJCC v7
- Stage IV Lung Large Cell Carcinoma AJCC v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
- 3-Dimensional Conformal Radiation Therapy Radiation
- Cisplatin Drug
- Intensity-Modulated Radiation Therapy Radiation
- Methoxyamine Drug
- Methoxyamine Hydrochloride Drug
- Pemetrexed Drug
- Pemetrexed Disodium Drug
Radiation · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2015
- Primary completion
- Feb 26, 2020
- Completion
- Jun 13, 2022
- Last update posted
- Jun 29, 2022
2015 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02535325, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 29, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02535325 live on ClinicalTrials.gov.